Our top pick for
Genmab A/S is a biotechnology business based in the US. Genmab A/S shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Genmab A/S employs 712 staff and has a market cap (total outstanding shares value) of USD$24.4 billion.
|52-week range||USD$16.24 - USD$44.83|
|50-day moving average||USD$41.3085|
|200-day moving average||USD$38.2094|
|Wall St. target price||USD$42.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$33.1853|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Genmab A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genmab A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Genmab A/S shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Genmab A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4684. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$5.4 billion|
|Return on assets TTM||27.27%|
|Return on equity TTM||36.46%|
|Market capitalisation||USD$24.4 billion|
TTM: trailing 12 months
There are currently 428,044 Genmab A/S shares held short by investors – that's known as Genmab A/S's "short interest". This figure is 49.6% down from 848,966 last month.
There are a few different ways that this level of interest in shorting Genmab A/S shares can be evaluated.
Genmab A/S's "short interest ratio" (SIR) is the quantity of Genmab A/S shares currently shorted divided by the average quantity of Genmab A/S shares traded daily (recently around 586361.64383562). Genmab A/S's SIR currently stands at 0.73. In other words for every 100,000 Genmab A/S shares traded daily on the market, roughly 730 shares are currently held short.
However Genmab A/S's short interest can also be evaluated against the total number of Genmab A/S shares, or, against the total number of tradable Genmab A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genmab A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genmab A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genmab A/S shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genmab A/S.
Find out more about how you can short Genmab A/S stock.
We're not expecting Genmab A/S to pay a dividend over the next 12 months.
Genmab A/S's shares were split on a 5:1 basis on 1 May 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab A/S shares which in turn could have impacted Genmab A/S's share price.
Over the last 12 months, Genmab A/S's shares have ranged in value from as little as $16.24 up to $44.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab A/S's is 0.5638. This would suggest that Genmab A/S's shares are less volatile than average (for this exchange).
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.